Rathbone Brothers plc acquired a new stake in Boston Scientific Co. (NYSE:BSX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 78,071 shares of the medical equipment provider’s stock, valued at approximately $3,006,000.

Several other large investors also recently modified their holdings of the company. First American Trust FSB lifted its position in shares of Boston Scientific by 1.3% in the third quarter. First American Trust FSB now owns 113,375 shares of the medical equipment provider’s stock valued at $4,365,000 after acquiring an additional 1,470 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Boston Scientific by 3.1% in the second quarter. Cubist Systematic Strategies LLC now owns 51,105 shares of the medical equipment provider’s stock valued at $1,671,000 after acquiring an additional 1,547 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Boston Scientific by 103.8% in the second quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock valued at $102,000 after acquiring an additional 1,594 shares in the last quarter. Somerset Group LLC lifted its position in shares of Boston Scientific by 3.4% in the second quarter. Somerset Group LLC now owns 49,838 shares of the medical equipment provider’s stock valued at $1,630,000 after acquiring an additional 1,638 shares in the last quarter. Finally, Bainco International Investors lifted its position in shares of Boston Scientific by 0.8% in the second quarter. Bainco International Investors now owns 208,514 shares of the medical equipment provider’s stock valued at $6,818,000 after acquiring an additional 1,729 shares in the last quarter. Institutional investors and hedge funds own 90.93% of the company’s stock.

Several research firms recently weighed in on BSX. Morgan Stanley increased their target price on Boston Scientific from $38.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 2nd. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a research report on Tuesday, September 25th. Wells Fargo & Co increased their target price on Boston Scientific from $38.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. Needham & Company LLC reiterated a “strong-buy” rating and set a $43.00 target price (up from $39.00) on shares of Boston Scientific in a research report on Friday, September 7th. Finally, Argus increased their target price on Boston Scientific to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, September 5th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. Boston Scientific presently has an average rating of “Buy” and a consensus price target of $36.87.

Shares of NYSE:BSX opened at $36.99 on Friday. The stock has a market cap of $53.24 billion, a price-to-earnings ratio of 29.17, a PEG ratio of 2.68 and a beta of 0.59. The company has a quick ratio of 0.60, a current ratio of 0.83 and a debt-to-equity ratio of 0.62. Boston Scientific Co. has a 12 month low of $24.54 and a 12 month high of $39.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.34 by $0.07. The company had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.47 billion. Boston Scientific had a return on equity of 26.35% and a net margin of 5.48%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.32 earnings per share. Research analysts predict that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $36.02, for a total transaction of $180,100.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP John Bradley Sorenson sold 10,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $35.86, for a total value of $358,600.00. Following the sale, the senior vice president now owns 44,636 shares of the company’s stock, valued at $1,600,646.96. The disclosure for this sale can be found here. Insiders have sold 295,834 shares of company stock valued at $11,038,468 over the last 90 days. 0.73% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.